Remdesivir Showing Promise In Some COVID-19 Patients
Gilead’s drug candidate Remdesivir is showing some signs of positive proof of concept in hospitalized COVID-19 patients; it outperformed placebo by 31% in a clinical trial sponsored by the NIH according to the agency. NIH’s National Institute of Allergy and Infectious Disease has released preliminary data showing the study meeting the primary outcome of statistical …